PTPI (Petros Pharmaceuticals) Effective Interest Rate on Debt %: 0.00% (As of Mar. 2026)


What is Petros Pharmaceuticals Effective Interest Rate on Debt %?

Petros Pharmaceuticals PTPI +5.71% Effective Interest Rate on Debt % is 0.00% as of Mar. 2026.

Effective Interest Rate on Debt % is the usage rate that a borrower actually pays on a debt. It is calculated as the positive value of Interest Expense divided by its average total debt. Total debt equals to Long-Term Debt & Capital Lease Obligation plus Short-Term Debt & Capital Lease Obligation. Petros Pharmaceuticals's annualized positive value of Interest Expense for the quarter that ended in Mar. 2026 was $0.00 Mil. Petros Pharmaceuticals's average total debt for the quarter that ended in Mar. 2026 was $0.00 Mil. Therefore, Petros Pharmaceuticals's annualized Effective Interest Rate on Debt % for the quarter that ended in Mar. 2026 was N/A%.

Petros Pharmaceuticals  (OTCPK:PTPI) Effective Interest Rate on Debt % Explanation

Effective Interest Rate on Debt % measures the usage rate that a borrower actually pays on a debt.

Petros Pharmaceuticals Effective Interest Rate on Debt % Related Terms

Petros Pharmaceuticals Effective Interest Rate on Debt % Historical Data

* Premium members only.

The historical data trend for Petros Pharmaceuticals's Effective Interest Rate on Debt % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Petros Pharmaceuticals Effective Interest Rate on Debt % Chart

Petros Pharmaceuticals Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Effective Interest Rate on Debt %
Get a 7-Day Free Trial 9.74 11.59 5.90 6.78 0.00

Petros Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Effective Interest Rate on Debt % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

PTPI vs STEK, KOAN, GCAN: Effective Interest Rate on Debt % Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Petros Pharmaceuticals's Effective Interest Rate on Debt %, along with its competitors' market caps and Effective Interest Rate on Debt % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Petros Pharmaceuticals Effective Interest Rate on Debt % vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Petros Pharmaceuticals's Effective Interest Rate on Debt % distribution charts can be found below:

* The bar in red indicates where Petros Pharmaceuticals's Effective Interest Rate on Debt % falls into.


Petros Pharmaceuticals Effective Interest Rate on Debt % Calculation

Petros Pharmaceuticals's annualized Effective Interest Rate on Debt % for the fiscal year that ended in Dec. 2025 is calculated as

Effective Interest Rate on Debt %
=-1  *  Interest Expense/( (Total Debt  (A: Dec. 2024 )+Total Debt  (A: Dec. 2025 ))/ count )
=-1  *  0/( (0+0)/ 1 )
=-1  *  0/0
=N/A %

where

Total Debt  (A: Dec. 2024 )
=Long-Term Debt & Capital Lease Obligation + Short-Term Debt & Capital Lease Obligation
=0 + 0
=0

Total Debt  (A: Dec. 2025 )
=Long-Term Debt & Capital Lease Obligation + Short-Term Debt & Capital Lease Obligation
=0 + 0
=0

Petros Pharmaceuticals's annualized Effective Interest Rate on Debt % for the quarter that ended in Mar. 2026 is calculated as

Effective Interest Rate on Debt %
=-1  *  Interest Expense/( (Total Debt  (Q: Dec. 2025 )+Total Debt  (Q: Mar. 2026 ))/ count )
=-1  *  0/( (0+0)/ 1 )
=-1  *  0/0
=N/A %

where

Total Debt  (Q: Dec. 2025 )
=Long-Term Debt & Capital Lease Obligation + Short-Term Debt & Capital Lease Obligation
=0 + 0
=0

Total Debt  (Q: Mar. 2026 )
=Long-Term Debt & Capital Lease Obligation + Short-Term Debt & Capital Lease Obligation
=0 + 0
=0

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Effective Interest Rate on Debt %, the Interest Expense of the last fiscal year and the average total debt over the fiscal year are used. In calculating the quarterly data, the Interest Expense data used here is four times the quarterly (Mar. 2026) interest expense data. Effective Interest Rate on Debt % is displayed in the 30-year financial page.

What does a Effective Interest Rate on Debt % of 0.00% mean?
Petros Pharmaceuticals (PTPI) has a Effective Interest Rate on Debt % of 0.00% as of Mar. 2026. Effective interest rate on debt is the rate a company actually pays on its debt. View historical data on Petros Pharmaceuticals and its competitors.
Is Petros Pharmaceuticals' Effective Interest Rate on Debt % too high?
Petros Pharmaceuticals' current Effective Interest Rate on Debt % is 0.00%.
How does Petros Pharmaceuticals' Effective Interest Rate on Debt % compare to STEK and KOAN?
Petros Pharmaceuticals' Effective Interest Rate on Debt % of 0.00% can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Effective Interest Rate on Debt % for a Drug Manufacturers company?
A good Effective Interest Rate on Debt % depends on the Drug Manufacturers industry context. However, Effective Interest Rate on Debt % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Effective Interest Rate on Debt % mean?
A high Effective Interest Rate on Debt % can signal that a stock is expensive relative to its fundamentals. Effective interest rate on debt is the rate a company actually pays on its debt. View historical data on Petros Pharmaceuticals and its competitors. Petros Pharmaceuticals's current Effective Interest Rate on Debt % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Petros Pharmaceuticals stock overvalued right now?
Petros Pharmaceuticals (PTPI) has a current Effective Interest Rate on Debt % of 0.00%. The current Effective Interest Rate on Debt % is 0.00%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Effective Interest Rate on Debt % calculated?
Effective Interest Rate on Debt % is calculated from a company's financial statements. For Petros Pharmaceuticals (PTPI), the current Effective Interest Rate on Debt % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Petros Pharmaceuticals Business Description

Address 1185 Avenue of the Americas, 3rd Floor, New York, NY, USA, 10036
Petros Pharmaceuticals Inc is a men's health pharmaceutical company. The Company is working towards the goal of becoming an innovator in the emerging self-care market, driving expanded access to key nonprescription pharmaceuticals as Over-the-Counter and nonprescription drug products with additional conditions for nonprescription use (ACNU Products) treatment options. Petros is pursuing the development of a proprietary integrated technology solutions platform containing two components: SaaS, designed to assist pharmaceutical companies in operationalizing and commercializing an Rx-to-OTC switch as an element in the development of an ACNU Product, and a potential Software as a Medical Device component, which guides the consumer in navigating appropriate self-selection or deselection.